Selahattin Kurter
Psychiatry · Milwaukee, WINPI 1164596615
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $10,320 of the $17,135 with a category attached, or 60.2%. AbbVie accounts for 68.8% of it on its own, with 34 other manufacturers making up the rest. Reporting peaked in 2019 at $8,761 and has fallen 82.5% since, to $1,529 in 2025. Among psychiatry clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 410 payments — averaging $41.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$12K
- Lundbeck LLC$793
- Alkermes, Inc.$664
- Orexo US, Inc.$397
- Sunovion Pharmaceuticals Inc.$383
- Otsuka America Pharmaceutical, Inc.$362
- plus $3K from 29 others
What the payments were for
- Speaking & faculty fees$10,32060%
- Travel & lodging$871%
- Food & beverage$6,47738%
- Education$2511%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 108 | $11,797 |
| Lundbeck LLC | 49 | $793 |
| Alkermes, Inc. | 31 | $664 |
| Orexo US, Inc. | 25 | $397 |
| Sunovion Pharmaceuticals Inc. | 25 | $383 |
| Otsuka America Pharmaceutical, Inc. | 22 | $362 |
| Vanda Pharmaceuticals Inc. | 18 | $285 |
| Gilead | 12 | $240 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $236 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $227 |
| Indivior Inc. | 11 | $224 |
| Johnson & Johnson | 10 | $178 |
| Teva Pharmaceuticals USA, Inc. | 7 | $173 |
| E.r. Squibb & Sons, L.L.C. | 8 | $167 |
| Corium, LLC | 6 | $124 |
| Supernus Pharmaceuticals, Inc. | 6 | $121 |
| Bausch Health US, LLC | 5 | $98 |
| Axsome Therapeutics, Inc. | 4 | $83 |
| Shire North American Group Inc | 5 | $79 |
| Tris Pharma Inc | 4 | $78 |
| Neurocrine Biosciences, Inc. | 4 | $76 |
| Ironshore Pharmaceuticals Inc. | 3 | $49 |
| Braeburn Inc. | 3 | $49 |
| Eisai Inc. | 2 | $43 |
| Sage Therapeutics, LLC | 1 | $29 |
| USWM, LLC | 2 | $27 |
| MDD US Operations, LLC | 1 | $25 |
| Avanir Pharmaceuticals, Inc. | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Adlon Therapeutics L.p. | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Neuronetics, Inc. | 1 | $15 |
| Merck | 1 | $15 |
| Rhodes Pharmaceuticals L.p. | 1 | $15 |
| Vertical Pharmaceuticals, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,135 in reported general payments places this provider in the 95th percentile of 543 psychiatry providers in Wisconsin.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 11 | $16,240 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 128 | $14,315 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 16 | $10,798 |
| VyvanseLisdexamfetamine Dimesylate | 22 | $7,315 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 15 | $4,942 |
| Aripiprazole | 22 | $4,747 |
| Bupropion XlBupropion Hcl | 60 | $1,657 |
| Risperidone | 17 | $1,588 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 29 | $955 |
| Methylphenidate ErMethylphenidate Hcl | 20 | $953 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 22 | $874 |
| Escitalopram Oxalate | 50 | $569 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 15 | $517 |
| Quetiapine Fumarate | 22 | $501 |
| Lamotrigine | 24 | $473 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $11,797 | $16,24011 claims |
| Indivior Inc.Suboxone | $224 | $10,79816 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $236 | $7,31522 claims |
| Orexo US, Inc.Zubsolv | $397 | $4,94215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 543 psychiatry providers in Wisconsin.
Other psychiatry in Milwaukee
- Thomas IlicMilwaukee$324K
- Jay WinstonMilwaukee$238K
- Joseph BurgarinoMilwaukee$111K
- Jacob BehrensMilwaukee$94K
- Harold HarschMilwaukee$8K
- Ajay SehgalMilwaukee$7K
- James WinstonMilwaukee$7K
- Edgar JacksonMilwaukee$5K
- Ali ArtarMilwaukee$5K
- Robert RuskiewiczMilwaukee$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.